Floatz logo

Tezemlimogene Daxadenorepvec

Periampullary Cancer

DNAtrix, Inc.gene_therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Periampullary Cancer cohort.

Asset / SponsorPhaseRating
HUMAN FIBRINOGEN
Asan Medical Center
Phase 4BB
N-BUTYL CYANOACRYLATE
Minia University
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2B
Cediranib
National Cancer Institute (NCI)
Phase 2CCC
Cipralex
Case Comprehensive Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Tezemlimogene Daxadenorepvec is also rated in:

gastrointestinal stromal tumorDormant
CC
Indicative ·
43 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
adult glioblastomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →